RPG Life Sciences Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Press release".
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences announced its financial results for the quarter ended June 30, 2025. Revenue from operations grew 2.1% year-on-year to Rs. 168.9 crores (from Rs. 165.4 crores), while quarter-on-quarter revenue rose a stronger 18.1%. Profit before tax came in at Rs. 35.4 crores, marginally lower than Rs. 36.0 crores in the same quarter last year. The company maintained a healthy EBITDA margin of 24.1%. Management highlighted continued strength in domestic formulations and outlined plans to grow international formulations and API segments through new customers, new markets, and new molecules. The company also indicated it is actively exploring inorganic growth opportunities across formulations and APIs.
Modest top-line growth and broadly stable profitability suggest steady but unspectacular quarterly performance. Management's focus on inorganic expansion could be a future growth catalyst for shareholders, though near-term stock reaction is likely to be muted given the small decline in PBT.